Treatment for preventing the recurrence of neuromyelitis optica spectrum disorders with positive aquaporin-4 immunoglobulin G antibody

Guo Shougang

PDF(480 KB)
PDF(480 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (05) : 593-596. DOI: 10.13406/j.cnki.cyxb.003495
Treatment of neuroimmune diseases

Treatment for preventing the recurrence of neuromyelitis optica spectrum disorders with positive aquaporin-4 immunoglobulin G antibody

Author information +
History +

Abstract

Neuromyelitis optica spectrum disorders（NMOSD） is an autoimmune-mediated central nervous system disorder characterized by optic neuritis and transverse myelitis. NMOSD is mainly caused by aquaporin-4（AQP4） immunoglobulin G（IgG） antibody and has the characteristics of high recurrence and disability rates. Each time of recurrence may lead to gradual accumulation of nerve damage and disability，and therefore，drugs for effective prevention of recurrence should be used as early as possible to reduce recurrence rate and improve the long-term prognosis of patients. At present，with the in-depth studies on the pathogenesis of NMOSD， new monoclonal antibody drugs for corresponding targets continue to emerge. This article reviews the treatment methods for preventing the recurrence of NMOSD with positive AQP4-IgG antibody in the chronic stage.

Key words

neuromyelitis optica spectrum disorders / aquaporin-4 / targeted drugs

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Guo Shougang. Treatment for preventing the recurrence of neuromyelitis optica spectrum disorders with positive aquaporin-4 immunoglobulin G antibody. Journal of Chongqing Medical University. 2024, 49(05): 593-596 https://doi.org/10.13406/j.cnki.cyxb.003495

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Carnero Contentti E， Correale J. Neuromyelitis optica spectrum disorders：from pathophysiology to therapeutic strategies[J]. J Neuroinflammation，2021，18（1）：208．
本文引用 [2]
2
Soltys J， Liu YT， Ritchie A，et al. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica[J]. J Clin Invest，2019，129（5）：2000-2013．
本文引用 [1]
3
贾琳琳，蒋玙姝，张梦歌，等. 视神经脊髓炎谱系疾病发病机制的研究进展[J]. 实用临床医药杂志，2022，26（7）：132-138．
Jia LL， Jiang YS， Zhang MG，et al. Research progress on pathogenesis of neuromyelitis optic spectrum diseases[J]. J Clin Med Pract，2022，26（7）：132-138．
本文引用 [1]
4
Wilson R， Makuch M， Kienzler AK，et al. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica[J]. Brain，2018，141（4）：1063-1074．
本文引用 [1]
5
Liu J， Tan GJ， Li B，et al. Serum aquaporin 4-immunoglobulin G titer and neuromyelitis optica spectrum disorder activity and severity：a systematic review and meta-analysis[J]. Front Neurol，2021，12：746959．
本文引用 [1]
6
张亚坤，郝晓迪，谭蕾蕾，等. 伊奈利珠单抗治疗视神经脊髓炎谱系疾病的临床研究进展[J]. 中国神经免疫学和神经病学杂志，2023，30（5）：368-373．
Zhang YK， Hao XD， Tan LL，et al. Clinical research progress of inebilizumab in the treatment of neuromyelitis optica spectrum disorders[J]. Chin J Neuroimmunol Neurol，2023，30（5）：368-373．
本文引用 [1]
7
Pittock SJ， Zekeridou A， Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials[J]. Nat Rev Neurol，2021，17（12）：759-773．
本文引用 [1]
8
刘乃榕，崔萍萍，张美妮. 利妥昔单抗治疗视神经脊髓炎谱系疾病的应用方案研究进展[J]. 中国神经免疫学和神经病学杂志，2021，28（3）：238-242．
Liu NR， Cui PP， Zhang MN. Research progress in the regimen of rituximab in neuromyelitis optica spectrum diseases[J]. Chin J Neuroimmunol Neurol，2021，28（3）：238-242．
本文引用 [1]
9
Barreras P， Vasileiou ES， Filippatou AG，et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease[J]. Neurology，2022，99（22）：e2504-e2516．
本文引用 [1]
10
Gao FL， Chai BY， Gu C，et al. Effectiveness of rituximab in neuromyelitis optica：a meta-analysis[J]. BMC Neurol，2019，19（1）：36．
本文引用 [1]
11
Li T， Zhang LJ， Zhang QX，et al. Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab[J]. J Neuroimmunol，2018，316：107-111．
本文引用 [1]
12
Zhan YB， Zhao M， Li XJ，et al. A meaningful exploration of ofatumumab in refractory NMOSD：a case report[J]. Front Immunol，2023，14：1208017．
本文引用 [1]
13
Cree BAC， Bennett JL， Kim HJ，et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder（N-MOmentum）：a double-blind，randomised placebo-controlled phase 2/3 trial[J]. Lancet，2019，394（10206）：1352-1363．
本文引用 [1]
14
Giglhuber K， Berthele A. Adverse events in NMOSD therapy[J]. Int J Mol Sci，2022，23（8）：4154．
本文引用 [3]
15
Zhang C， Zhang MN， Qiu W，et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder（TANGO）：an open-label，multicentre，randomised，phase 2 trial[J]. Lancet Neurol，2020，19（5）：391-401．
本文引用 [1]
16
王玉鸽，邱　伟，胡学强. 萨特利珠单抗治疗视神经脊髓炎谱系疾病的研究进展[J]. 中国神经免疫学和神经病学杂志，2021，28（5）：411-414．
Wang YG， Qiu W， Hu XQ. The advances of satralizumab in the treatment of neuromyelitis optica spectrum disorder[J]. Chin J Neuroimmunol Neurol，2021，28（5）：411-414．
本文引用 [1]
17
Kleiter I， Traboulsee A， Palace J，et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar[J]. Neurol Neuroimmunol Neuroinflamm，2023，10（1）：e200071．
本文引用 [1]
18
Rother RP， Rollins SA， Mojcik CF，et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria[J]. Nat Biotechnol，2007，25（11）：1256-1264．
本文引用 [1]
19
Wingerchuk DM， Fujihara K， Palace J，et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD[J]. Ann Neurol，2021，89（6）：1088-1098．
本文引用 [1]
20
Qin C， Tian DS， Zhou LQ，et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders：phase 1 trial interim results[J]. Signal Transduct Target Ther，2023，8（1）：5．
本文引用 [1]
21
Fu Y， Yan YP， Qi Y，et al. Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder：a pilot，2-year observational study[J]. CNS Neurosci Ther，2016，22（8）：677-685．
本文引用 [2]

Comments

PDF(480 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉